Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review - PubMed (original) (raw)
. 2019 Jun;68(6):1115-1126.
doi: 10.1136/gutjnl-2018-318081. Epub 2019 Apr 3.
Arne Bokemeyer 1, Mark Baker 2, Ren Mao 3 4, Claire E Parker 5, Tran Nguyen 5, Christopher Ma 5 6, Julián Panés 7, Jordi Rimola 8, Joel G Fletcher 9, Vipul Jairath 5 10 11, Brian G Feagan 5 10 11, Florian Rieder 4 12; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium.
Affiliations
- PMID: 30944110
- PMCID: PMC6580870
- DOI: 10.1136/gutjnl-2018-318081
Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review
Dominik Bettenworth et al. Gut. 2019 Jun.
Abstract
Patients with Crohn's disease commonly develop ileal and less commonly colonic strictures, containing various degrees of inflammation and fibrosis. While predominantly inflammatory strictures may benefit from a medical anti-inflammatory treatment, predominantly fibrotic strictures currently require endoscopic balloon dilation or surgery. Therefore, differentiation of the main components of a stricturing lesion is key for defining the therapeutic management. The role of endoscopy to diagnose the nature of strictures is limited by the superficial inspection of the intestinal mucosa, the lack of depth of mucosal biopsies and by the risk of sampling error due to a heterogeneous distribution of inflammation and fibrosis within a stricturing lesion. These limitations may be in part overcome by cross-sectional imaging techniques such as ultrasound, CT and MRI, allowing for a full thickness evaluation of the bowel wall and associated abnormalities. This systematic literature review provides a comprehensive summary of currently used radiologic definitions of strictures. It discusses, by assessing only manuscripts with histopathology as a gold standard, the accuracy for diagnosis of the respective modalities as well as their capability to characterise strictures in terms of inflammation and fibrosis. Definitions for strictures on cross-sectional imaging are heterogeneous; however, accuracy for stricture diagnosis is very high. Although conventional cross-sectional imaging techniques have been reported to distinguish inflammation from fibrosis and grade their severity, they are not sufficiently accurate for use in routine clinical practice. Finally, we present recent consensus recommendations and highlight experimental techniques that may overcome the limitations of current technologies.
Keywords: Crohn’s disease; fibrosis.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: DB is on the advisory board or consultant for AbbVie, Dr Falk Foundation, Ferring, MSD, Pharmacosmos, Roche, Takeda, Tillotts Pharma and Vifor. MB receives support from Siemens Healthineers in the form of salary support, hardware and software for investigating the effect of lower exposure CT in detecting active Crohn’s disease. CEP is an employee of Robarts Clinical Trials. JP has received consultancy fees from AbbVie, Arena, Boehringer Ingelheim, Galapagos, Genentech, Janssen, MSD, Novartis, Pfizer, Robarts, Second Genome, Takeda, Theravance, TiGenix and Topivert. JR is on the advisory board or consultant for Robarts Clinical Trials, Takeda and TiGenix and received research grant from AbbVie and Genentech. JGF receives grants to his institution from Siemens Healthineers and Medtronic. VJ receives salary support from the John and Susan McDonald Endowed IBD Chair at Western University, London, Ontario, Canada; consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena Pharmaceuticals, Genentech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Robarts Clinical Trials, Topivert and Celltrion; speaker fees from Takeda, Janssen, Shire, Ferring, AbbVie and Pfizer. BGF has received grant/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma, AbbVie, Novartis Pharmaceuticals, Centocor, Elan/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix and Wyeth Pharmaceuticals; consulting fees from Millennium Pharmaceuticals, Merck, Centocor, Elan/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, AstraZeneca, Serono, Genentech, Tillotts Pharma, Unity Pharmaceuticals, Albireo Pharma, Given Imaging, Salix Pharmaceuticals, Novonordisk, GSK, ActoGenix, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, GiCare Pharma and Sigmoid Pharma; and speaker’s bureau fees from UCB, AbbVie and J&J/Janssen. FR is on the advisory board or consultant for AbbVie, Allergan, Celgene, Gossamer, Receptos, Thetis, UCB, Samsung, Pliant, Boehringer Ingelheim, Metacrine, Takeda, Allergan, Helmsley, RedX and Roche. RM has no conflicts of interest to declare.
Figures
Figure 1
Transabdominal ultrasonography, CT and MR enterography demonstrating a distal ileal stricture. (A) Ultrasound image depicting the three core items for stricture diagnosis wall thickness (W, bracket), luminal narrowing (L, bracket) and prestenotic dilation (D, double arrow). (B–D) CT enterography demonstrating a distal ileal stricture with imaging findings of active inflammation and partial small bowel obstruction. (B) Coronal image demonstrating a distal ileal stricture with wall thickening, luminal narrowing and mural stratification and hyperenhancement (large white arrow). Active inflammatory Crohn’s disease is also present in the terminal ileum (arrowhead), as is a short segment jejunal stricture (small white arrow). (C) Enlarged axial image through distal ileal stricture better demonstrates luminal narrowing and increased wall thickness (W, bracket). (D) Sagittal image through distal ileal stricture shows prestenotic bowel dilation (D, arrows) and luminal narrowing within the stricture (L, bracket). (E–G) MR enterography demonstrating a distal ileal stricture with imaging findings of active inflammation. (E) Coronal half-Fourier single-shot fast spin echo (HASTE) shows ileal stricture with wall thickening and luminal narrowing (large white arrow) with upstream dilation (D, arrows). (F) Axial HASTE shows cross section through the stricture demonstrating increased wall thickness and how wall thickening is measured (W, white bracket). (G) Postcontrast axial 3D volumetric interpolated breath hold examination (VIBE) shows wall thickening and mural stratification and hyperenhancement, indicating inflammation with luminal narrowing (L, bracket). The three core items for stricture diagnosis are increased wall thickness, luminal narrowing and prestenotic dilation. CTE, CT enterography; MRE, MR enterography.
Figure 2
Proposed ranges for key items used for stricture detection in cross-sectional imaging modalities. US, ultrasound.
Similar articles
- Real-Time Shear Wave Ultrasound Elastography Differentiates Fibrotic from Inflammatory Strictures in Patients with Crohn's Disease.
Chen YJ, Mao R, Li XH, Cao QH, Chen ZH, Liu BX, Chen SL, Chen BL, He Y, Zeng ZR, Ben-Horin S, Rimola J, Rieder F, Xie XY, Chen MH. Chen YJ, et al. Inflamm Bowel Dis. 2018 Sep 15;24(10):2183-2190. doi: 10.1093/ibd/izy115. Inflamm Bowel Dis. 2018. PMID: 29718309 Free PMC article. - Cross-sectional imaging for assessing intestinal fibrosis in Crohn's disease.
Zhong YK, Lu BL, Huang SY, Chen YJ, Li ZP, Rimola J, Li XH. Zhong YK, et al. J Dig Dis. 2020 Jun;21(6):342-350. doi: 10.1111/1751-2980.12881. J Dig Dis. 2020. PMID: 32418328 Review. - Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound.
Lu C, Rosentreter R, Delisle M, White M, Parker CE, Premji Z, Wilson SR, Baker ME, Bhatnagar G, Begun J, Bruining DH, Bryant R, Christensen B, Feagan BG, Fletcher JG, Jairath V, Knudsen J, Kucharzik T, Maaser C, Maconi G, Novak K, Rimola J, Taylor SA, Wilkens R, Rieder F; Stenosis Therapy and Anti‐Fibrotic Research (STAR) consortium. Lu C, et al. Aliment Pharmacol Ther. 2024 Apr;59(8):928-940. doi: 10.1111/apt.17918. Epub 2024 Mar 4. Aliment Pharmacol Ther. 2024. PMID: 38436124 Review. - MR enterography-histology comparison in resected pediatric small bowel Crohn disease strictures: can imaging predict fibrosis?
Barkmeier DT, Dillman JR, Al-Hawary M, Heider A, Davenport MS, Smith EA, Adler J. Barkmeier DT, et al. Pediatr Radiol. 2016 Apr;46(4):498-507. doi: 10.1007/s00247-015-3506-6. Epub 2015 Dec 5. Pediatr Radiol. 2016. PMID: 26638000 - An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease.
Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V. Rieder F, et al. Aliment Pharmacol Ther. 2018 Aug;48(3):347-357. doi: 10.1111/apt.14853. Epub 2018 Jun 19. Aliment Pharmacol Ther. 2018. PMID: 29920726 Free PMC article.
Cited by
- Computed tomography enterography radiomics and machine learning for identification of Crohn's disease.
Shi Q, Hao Y, Liu H, Liu X, Yan W, Mao J, Chen BT. Shi Q, et al. BMC Med Imaging. 2024 Nov 6;24(1):302. doi: 10.1186/s12880-024-01480-5. BMC Med Imaging. 2024. PMID: 39506676 Free PMC article. - Ustekinumab affects myofibroblast metabolism to alleviate intestinal fibrosis by targeting KDELC1 in Crohn's disease through multi-machine learning combined with single-cell sequencing analysis.
Ma S, Kang Y, Yang Z, Ji X, Chen R, Sun X. Ma S, et al. Front Med (Lausanne). 2024 Oct 22;11:1476592. doi: 10.3389/fmed.2024.1476592. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39502647 Free PMC article. - Deep-Learning, Radiomics and Clinic Based Fusion Models for Predicting Response to Infliximab in Crohn's Disease Patients: A Multicentre, Retrospective Study.
Cai W, Wu X, Guo K, Chen Y, Shi Y, Lin X. Cai W, et al. J Inflamm Res. 2024 Oct 25;17:7639-7651. doi: 10.2147/JIR.S484485. eCollection 2024. J Inflamm Res. 2024. PMID: 39473983 Free PMC article. - Elastography as a Discriminator Between Fibrotic and Inflammatory Strictures in Crohn's Disease: A Dead End or Bright Future in Clinical Decision-Making? Critical Review.
Kuczyńska M, Zbroja M, Drelich-Zbroja A. Kuczyńska M, et al. Diagnostics (Basel). 2024 Oct 16;14(20):2299. doi: 10.3390/diagnostics14202299. Diagnostics (Basel). 2024. PMID: 39451622 Free PMC article. Review. - Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease.
Ma C, Jairath V, Feagan BG, Peyrin-Biroulet L, Danese S, Sands BE, Panaccione R. Ma C, et al. Nat Rev Gastroenterol Hepatol. 2024 Nov;21(11):792-808. doi: 10.1038/s41575-024-00989-y. Epub 2024 Oct 8. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39379665 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical